Eli Lilly's Mounjaro just picked up new cardiovascular data, and investors are asking whether that heart benefit gives the stock a second growth engine beyond weight loss. The timing matters because Lilly has also been buying companies at a rapid clip, and Medicare's new GLP-1 discount is turning out to have real eligibility limits. Novo Nordisk had its own news too, with a fresh Wegovy trial result and a pediatric obesity study that could reshape how doctors think about treating young children.
Mounjaro's new heart benefit data is drawing attention from investors who have mostly valued Lilly on the strength of its weight loss franchise. If the drug's cardiovascular effects hold up as a distinct selling point, that gives Lilly a second story to tell beyond pounds lost, one that could open the door to a broader set of patients and prescribers who weigh heart risk heavily in their treatment decisions. Some analysts see this as the start of a new phase for the stock, where GLP-1 sales are no longer the only lever driving Lilly's valuation higher. That shift would not happen overnight, but it changes the conversation around what Mounjaro is worth to the company long term.
That broader growth story gets another boost from Lilly's acquisition spree, which has picked up pace in recent months. The company has been adding capabilities and pipeline assets through a series of deals, and some investors are trying to work out how much of that dealmaking could add to the stock price down the road. The logic is straightforward: if Lilly can pair strong existing sales with new assets bought at reasonable prices, the combination gives the stock more than one way to keep climbing. How much of that potential is already priced in remains an open question, and it is one Lilly's next earnings report may help answer.
Not every part of the GLP-1 story looks as favorable for patients, though. Medicare's new discount program for GLP-1 drugs does not cover everyone who might want in, and coverage rules mean some beneficiaries will still face costs the discount was meant to ease. That gap affects people who assumed the program would apply broadly, and it is a reminder that policy headlines do not always translate into access for every patient. Anyone relying on Medicare for these drugs would do well to check their own plan's rules rather than assume the discount applies to them.
While Lilly works through its own set of catalysts, Novo Nordisk added one of its own this week. A new trial result for Wegovy gives the company another data point to point to as it competes for share in a market Lilly is also chasing hard. For Novo, a fresh clinical win serves a similar purpose to Lilly's heart data: it gives investors and prescribers another reason to keep Wegovy in the conversation rather than ceding ground to newer competitors. The two companies are, in effect, racing to add reasons for patients and payers to choose their drug over the other's.
Novo Nordisk also has a study result touching a different population entirely. The study found that Wegovy helped 40% of young children in the trial overcome obesity, a result that speaks to a much younger age group than the adult weight loss market most GLP-1 coverage focuses on. That finding could matter for parents and pediatricians weighing treatment options for children who have not responded to other approaches, though any decision about a child's treatment should involve their own doctor rather than a headline number. It also gives Novo another avenue for Wegovy's use beyond the adult market Lilly is competing hardest for.
Taken together, today's news shows two large companies working from different angles to extend their GLP-1 franchises, one through new clinical data and one through acquisitions and pipeline expansion. For readers with a financial interest, the near-term signal to watch is how analysts and Lilly's next earnings call treat the heart data and deal spree separately, since conflating the two could overstate what either has actually proven. For readers with a personal or family interest in these drugs, the more useful step is to check your own Medicare plan's rules on the GLP-1 discount and, if a child's weight is the concern, to raise the pediatric study with their doctor directly rather than acting on the headline alone.
Key details
Mounjaro's new heart benefit data may fuel further growth for Lilly's stock.
Lilly's recent acquisition spree could add further momentum to its stock price.
Not everyone qualifies for the new Medicare discount on GLP-1 drugs.
A new trial result gives Novo Nordisk another growth catalyst for Wegovy.
A study found Wegovy helped 40% of young children overcome obesity.
Read this on GLP-1 Nation: https://glp1nation.com/edition/43
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.